TSE:SVA Sernova (SVA) Stock Price, News & Analysis C$0.19 -0.02 (-7.32%) As of 04/25/2025 03:50 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Sernova Stock (TSE:SVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sernova alerts:Sign Up Key Stats Today's RangeC$0.19▼C$0.2150-Day RangeC$0.15▼C$0.2252-Week RangeC$0.15▼C$0.47Volume106,260 shsAverage Volume146,661 shsMarket CapitalizationC$63.93 millionP/E RatioN/ADividend Yield7.86%Price TargetC$2.00Consensus RatingBuy Company OverviewSernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on Type 1 diabetes and thyroid disorders.Read More… Sernova Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreSVA MarketRank™: Sernova scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingSernova has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSernova has received no research coverage in the past 90 days.Read more about Sernova's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sernova is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sernova is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for SVA. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipSernova is a leading dividend payer. It pays a dividend yield of 7.86%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthSernova does not have a long track record of dividend growth.Read more about Sernova's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for SVA. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Sernova this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sernova insiders have not sold or bought any company stock.Percentage Held by Insiders12.13% of the stock of Sernova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.05% of the stock of Sernova is held by institutions.Read more about Sernova's insider trading history. Receive SVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter. Email Address SVA Stock News HeadlinesSernova Biotherapeutics Inc's (TSE:SVA) Shift From Loss To ProfitMarch 23, 2025 | finance.yahoo.comSernova Biotherapeutics Inc (SVA.TO)March 19, 2025 | finance.yahoo.comTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionApril 26, 2025 | Crypto 101 Media (Ad)Sernova Corp.: Sernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova BiotherapeuticsFebruary 11, 2025 | finanznachrichten.deJobs Reports Due for Next WeekJanuary 31, 2025 | theglobeandmail.comSernova Announces Appointment of Ross Haghighat as Chair of the Board and a Change of Name to Sernova BiotherapeuticsJanuary 30, 2025 | markets.businessinsider.comSchool of Visual ArtsNovember 1, 2024 | usnews.comSernova Announces Key New Executive AppointmentsOctober 11, 2024 | finance.yahoo.comSee More Headlines SVA Stock Analysis - Frequently Asked Questions How have SVA shares performed this year? Sernova's stock was trading at C$0.23 at the beginning of 2025. Since then, SVA stock has decreased by 15.6% and is now trading at C$0.19. View the best growth stocks for 2025 here. How do I buy shares of Sernova? Shares of SVA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Sernova own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sernova investors own include ARC Resources (ARX), Meta Platforms (META), Newron Pharmaceuticals (NWPHF), Sernova (SEOVF), AMC Entertainment (AMC), Advanced Micro Devices (AMD) and CloudMD Software & Services (DOC). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:SVA CIKN/A Webwww.sinovacbio.com Phone861082890088FaxN/AEmployees1,959Year FoundedN/APrice Target and Rating Average Stock Price TargetC$2.00 High Stock Price TargetC$2.50 Low Stock Price TargetC$1.50 Potential Upside/Downside+952.6%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-35,698,842.53 Net MarginsN/A Pretax MarginN/A Return on Equity473.85% Return on Assets-119.26% Debt Debt-to-Equity Ratio-4.40 Current Ratio0.32 Quick Ratio18.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.03 per share Price / Cash Flow6.15 Book ValueC($0.04) per share Price / Book-4.45Miscellaneous Outstanding Shares336,496,829Free FloatN/AMarket CapC$63.93 million OptionableNot Optionable Beta1.35 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (TSE:SVA) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDeepSeek’s Clear and Present DangerDeepSeek — the alleged “$5.5 million” AI project — isn’t an open-source breakthrough. It’s a Trojan horse.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sernova Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sernova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.